Investigating the role of RBM10-regulated alternative splicing in lung tumorigenesis
Investigating the role of RBM10-regulated alternative splicing in lung tumorigenesis
批准号:
10083717
负责人:
Peter S. Choi
金额:
$24.9万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-08 至 2022-01-31
关键词:
Advisory CommitteesAlternative SplicingCRISPR/Cas technologyCancer EtiologyCancer cell lineCandidate Disease GeneCellsCessation of lifeDana-Farber Cancer InstituteData SetDependenceDevelopmentEpidermal Growth Factor ReceptorEventExonsFacultyGene ExpressionGenesGeneticGenetic studyGenomicsGoalsHumanIn VitroInstitutesKRAS2 geneKRASG12DKnock-outLaboratoriesLeadLungLung AdenocarcinomaMalignant NeoplasmsMalignant neoplasm of lungMentorshipModelingMonitorMusMutationOncogenesPathogenesisPhenotypePositioning AttributeRNARNA SplicingRNA-Binding ProteinsResearchRoleSomatic MutationSurveysSynthetic GenesTherapeuticTranscriptTranslatingTumor Suppressor GenesWomanbasecancer cellcancer genomicscareer developmentgenome-wideimprovedin vivoloss of functionlung cancer celllung tumorigenesismenmutantnew therapeutic targetnovelnovel therapeutic interventiontenure track
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Large-scale genomic surveys of lung adenocarcinoma have revealed frequent mutations in the RNA-binding
protein RBM10. RBM10 mutations consist mainly of loss-of-function alterations, suggesting it may function as a
tumor suppressor gene. The main goals of this proposal are to investigate the role of RBM10 mutations in lung
tumorigenesis and to identify potential genetic dependencies specific to RBM10-deficient lung cancer cells. In
Aim 1, Rbm10 will be targeted directly in the mouse lung to assess the effects of Rbm10 loss-of-function in a
model of mutant KrasG12D-induced lung adenocarcinoma. In Aim 2, RNA transcripts that interact with RBM10
in lung cancer cells will be identified along with exons that are differentially spliced in the presence or absence
of RBM10. For each of the approaches in Aim 2, both human and mouse cancer cells will be studied, providing
a unique and powerful set of data for identifying the most conserved and functionally relevant targets of
RBM10. Finally, in Aim 3, a genome-wide CRISPR/Cas9 knockout screen will be carried out to find unique
vulnerabilities in RBM10 mutant cells. The proposed research plan will improve our understanding of how
disruptions to normal RNA splicing can contribute to human cancer and may yield novel therapeutic targets.
Dr. Peter Choi is currently a postdoctoral research fellow in the laboratory of Dr. Matthew Meyerson at the
Dana-Farber Cancer Institute and Broad Institute. His long-term goal is to lead an independent research group
in the study of how genetic alterations are functionally responsible for human cancer. He will carry out his
research during the K99 period under the primary mentorship of Dr. Meyerson, who is a leader in lung cancer
genomics. Additional mentorship will be provided by an advisory committee consisting of Drs. Hahn, Barbie,
Hammerman, and Harlow who will monitor Dr. Choi's scientific progress and career development, as well as
help guide his transition to a tenure-track faculty position.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring hidden determinants of splicing with genome-targeted proximity labeling
-
批准号:10245896
-
项目类别:
-
资助金额:$158.4万
-
财政年份:2021
-
负责人:Peter S. Choi
-
依托单位:
Defining the role of RBM10 in RNA processing and tumor suppression
-
批准号:8983196
-
项目类别:
-
资助金额:$5.6万
-
财政年份:2015
-
负责人:Peter S. Choi
-
依托单位:
海外基金